Leveraging the relationship between HIF1α and the TME through the SMURF2-HIF1α axis offers a multifaceted strategy for cancer treatment, particularly beneficial in tumors resistant to traditional therapies targeting the von Hippel-Lindau-HIF1α pathway (75, 104, 105). The gene discussed is HIF1A; the disease is cancer.